Fend Falko, Cabecadas José, Gaulard Philippe, Jaffe Elaine S, Kluin Philip, Kuzu Isinsu, Peterson Loann, Wotherspoon Andrew, Sundström Christer
Institute of Pathology and Comprehensive Cancer Center, Tübingen University Hospital, Tübingen, Germany.
J Hematop. 2012 Sep;5(3). doi: 10.1007/s12308-012-0148-6.
The increasing use of immunophenotypic and molecular techniques on lymphoid tissue samples without obvious involvement by malignant lymphoma has resulted in the increased detection of "early" lymphoid proliferations, which show some, but not all the criteria necessary for a diagnosis of malignant lymphoma. In most instances, these are incidental findings in asymptomatic individuals, and their biological behaviour is uncertain. In order to better characterize these premalignant conditions and to establish diagnostic criteria, a joint workshop of the European Association for Haematopathology and the Society of Hematopathology was held in Uppsala, Sweden, in September 2010. The panel reviewed and discussed more than 130 submitted cases and reached consensus diagnoses. Cases representing the nodal equivalent of monoclonal B-cell lymphocytosis (MBL) were discussed, as well as the "in situ" counterparts of follicular lymphoma (FL) and mantle cell lymphoma (MCL), topics that also stimulated discussions concerning the best terminology for these lesions. The workshop also addressed the borderland between reactive hyperplasia, and clonal proliferations such as pediatric marginal zone lymphoma and pediatric FL, which may have very limited capacity for progression. Virus-driven lymphoproliferations in the grey zone between reactive lesions and manifest malignant lymphoma were covered. Finally, early manifestations of T-cell lymphoma, both nodal and extranodal, and their mimics were addressed. This workshop report summarizes the most important conclusions concerning diagnostic features, as well as proposals for terminology and classification of early lymphoproliferations and tries to give some practical guidelines for diagnosis and reporting.
在无明显恶性淋巴瘤累及的淋巴组织样本上,免疫表型和分子技术的使用日益增多,这导致了“早期”淋巴增殖性病变的检出增加,这些病变显示出一些但并非所有诊断恶性淋巴瘤所需的标准。在大多数情况下,这些是无症状个体的偶然发现,其生物学行为尚不确定。为了更好地描述这些癌前病变并建立诊断标准,欧洲血液病理学协会和血液病理学会于2010年9月在瑞典乌普萨拉联合举办了一次研讨会。该小组审查并讨论了130多例提交的病例,并达成了共识诊断。讨论了代表单克隆B细胞淋巴细胞增多症(MBL)淋巴结等效病变的病例,以及滤泡性淋巴瘤(FL)和套细胞淋巴瘤(MCL)的“原位”对应病变,这些主题也引发了关于这些病变最佳术语的讨论。研讨会还讨论了反应性增生与克隆性增殖(如儿童边缘区淋巴瘤和儿童FL)之间的边界,这些克隆性增殖可能进展能力非常有限。涵盖了反应性病变和明显恶性淋巴瘤之间灰色地带的病毒驱动的淋巴增殖。最后,讨论了T细胞淋巴瘤的早期表现,包括淋巴结和结外表现及其相似病变。本研讨会报告总结了有关诊断特征的最重要结论,以及早期淋巴增殖性病变的术语和分类建议,并试图给出一些诊断和报告的实用指南。